Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 9 peer-reviewed journal articles Updated
Oncology

Staging and Classification (Bismuth-Corlette and MSKCC)

At a Glance

Perihilar cholangiocarcinoma (pCCA) is staged using the Bismuth-Corlette system to map tumor location in the bile ducts. This, along with checking if the tumor touches major blood vessels, helps doctors determine if the cancer can be safely removed with surgery and provides a clearer prognosis.

When you are diagnosed with perihilar cholangiocarcinoma (pCCA), you will hear doctors use different staging systems. In pCCA, a “stage” isn’t just about size—it is heavily dependent on the “real estate” the tumor occupies near the liver’s most critical blood vessels and bile ducts [1].

The Bismuth-Corlette Classification: The “Where”

The Bismuth-Corlette system is used to map exactly how high up into the bile ducts the tumor extends [2]. It tells the surgeon how much of the “plumbing” might need to be removed:

  • Type I: The tumor is below the point where the right and left ducts meet.
  • Type II: The tumor has reached the junction (confluence).
  • Type IIIa / IIIb: The tumor involves the junction and extends into the right (IIIa) or left (IIIb) ducts.
  • Type IV: The tumor extends into both the right and left ducts, or is in multiple separate locations [2].

Why Traditional Staging is Often Not Enough

Most cancers are staged using the AJCC (American Joint Committee on Cancer) system (Stages I-IV). However, research shows that the AJCC 8th edition has a “poor to moderate” ability to predict a patient’s actual prognosis for pCCA [3][4]. It often fails to account for the most crucial factor: resectability (whether the tumor can be safely removed by surgery).

Evaluating Vascular Involvement

Because standard staging has limits, specialized centers focus heavily on vascular involvement. A tumor’s relationship with the portal vein (the main vein to the liver) or the hepatic artery (the main artery) often determines if surgery is possible [5][6]. If a tumor wraps around these vessels on both the left and right sides, it may be considered unresectable [7].

Nomograms: A Personalized Map

Because every case is unique, your doctor may use a nomogram, such as the one developed by Memorial Sloan Kettering (MSKCC) [8]. This is a statistical tool that combines multiple factors—like your Bismuth type and vascular involvement—to give a more accurate and personalized prediction of your outcome than a simple AJCC stage ever could [9][8]. Ask your team if they have calculated a nomogram score to get the most accurate picture of your disease.

Common questions in this guide

What is the Bismuth-Corlette classification for pCCA?
The Bismuth-Corlette system maps how high up into the bile ducts a perihilar cholangiocarcinoma tumor extends. It uses Types I through IV to help surgeons understand the exact location of the tumor and determine how much tissue might need to be removed.
Why is standard cancer staging not enough for perihilar cholangiocarcinoma?
Traditional AJCC staging focuses on tumor size and spread, but it often struggles to predict a patient's actual prognosis for pCCA. It fails to adequately account for resectability, which is whether the tumor can be safely removed by surgery.
What does vascular involvement mean on my pCCA imaging?
Vascular involvement refers to whether the tumor is touching or wrapping around major liver blood vessels, like the portal vein or hepatic artery. This is one of the most critical factors your care team uses to determine if the cancer can be safely removed with surgery.
What is a nomogram and why did my doctor mention it?
A nomogram is a specialized statistical tool that combines multiple details about your specific cancer, such as your Bismuth type and vascular involvement. Tools like the MSKCC nomogram provide a more personalized and accurate estimate of your prognosis than standard staging alone.
Does Bismuth-Corlette Type IV mean I have Stage IV cancer?
No, they mean different things. In the Bismuth-Corlette system, Type IV simply describes the location of the tumor extending into both the right and left bile ducts. Traditional Stage IV means the cancer has spread to distant organs in the body.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my Bismuth-Corlette classification (Type I, II, III, or IV)?
  2. 2.Does my imaging show any involvement of the portal vein or hepatic artery? Is it on one side or both?
  3. 3.Can you use a prognostic nomogram (like the MSKCC tool) to give me a more personalized estimate of my survival probability?
  4. 4.Is my tumor 'resectable' based on its current vascular involvement?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (9)
  1. 1

    MDCT assessment of resectability in hilar cholangiocarcinoma.

    Ni Q, Wang H, Zhang Y, et al.

    Abdominal radiology (New York) 2017; (42(3)):851-860 doi:10.1007/s00261-016-0943-0.

    PMID: 27770159
  2. 2

    Prognostic impact of the Bismuth-Corlette classification: Higher rates of local unresectability in stage IIIb hilar cholangiocarcinoma.

    Passeri MJ, Baimas-George MR, Sulzer JK, et al.

    Hepatobiliary & pancreatic diseases international : HBPD INT 2020; (19(2)):157-162 doi:10.1016/j.hbpd.2020.02.001.

    PMID: 32088126
  3. 3

    Prognostic Relevance of the Eighth Edition of TNM Classification for Resected Perihilar Cholangiocarcinoma.

    Hau HM, Meyer F, Jahn N, et al.

    Journal of clinical medicine 2020; (9(10)) doi:10.3390/jcm9103152.

    PMID: 33003424
  4. 4

    Comparison of the 7th and 8th editions of the American Joint Committee on Cancer Staging Systems for perihilar cholangiocarcinoma.

    Ruzzenente A, Bagante F, Ardito F, et al.

    Surgery 2018; (164(2)):244-250 doi:10.1016/j.surg.2018.03.012.

    PMID: 29801730
  5. 5

    Evaluating the Clinical Applicability of the European Staging System for Perihilar Cholangiocarcinoma.

    Ismael HN, Loyer E, Kaur H, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2016; (20(4)):741-7 doi:10.1007/s11605-016-3075-5.

    PMID: 26801328
  6. 6

    Machine-learning radiomics to predict early recurrence in perihilar cholangiocarcinoma after curative resection.

    Qin H, Hu X, Zhang J, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2021; (41(4)):837-850 doi:10.1111/liv.14763.

    PMID: 33306240
  7. 7

    A New Strategy of Liver Transplantation for Locally Advanced Unresectable Perihilar Cholangiocarcinoma Using Living Grafts With Simultaneous Resection of Recipients' Hepatic Artery and Portal Vein Without Neoadjuvant Radiation: A Case Report.

    Miyagi S, Fujio A, Nakagawa K, et al.

    Transplantation proceedings 2022; (54(6)):1643-1647 doi:10.1016/j.transproceed.2022.03.054.

    PMID: 35810018
  8. 8

    Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram.

    Groot Koerkamp B, Wiggers JK, Gonen M, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2015; (26(9)):1930-1935 doi:10.1093/annonc/mdv279.

    PMID: 26133967
  9. 9

    A novel nomogram for adult primary perihilar cholangiocarcinoma and considerations concerning lymph node dissection.

    Zhang Q, Liu Z, Liu S, et al.

    Frontiers in surgery 2022; (9()):965401 doi:10.3389/fsurg.2022.965401.

    PMID: 36684342

This page provides educational information about perihilar cholangiocarcinoma staging and classification systems. Always consult your oncology team to interpret your specific imaging results, tumor stage, and treatment options.

Get notified when new evidence is published on Perihilar cholangiocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.